VOLTAREN-XR
LOE ApproachingNDAORALTABLET, EXTENDED RELEASE
Approved
Mar 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 4h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VOLTAREN-XR is an extended-release oral tablet formulation of diclofenac, a nonsteroidal anti-inflammatory drug (NSAID). The mechanism of action involves inhibition of cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis to decrease inflammation and pain. It is used for management of mild to moderate pain and inflammatory conditions.
LOE Approaching
With LOE approaching, the brand team is likely in transition or defensive mode; opportunities may shift toward lifecycle management or transition roles rather than growth-focused positions.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on VOLTAREN-XR offers limited growth trajectory given its LOE-approaching lifecycle stage and mature market position. Career development would focus on defensive brand strategies, market share retention, and potential transition to generic or lifecycle extension roles.
Brand ManagerField Sales Representative
Worked on VOLTAREN-XR at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.